Forte Protein Inc.

Forte Protein uses a plant-based technology to produce a broad spectrum of meat, fish, and dairy proteins without the need for animals eliminating the carbon footprint involved in animal agriculture.

Ratio Therapeutics

A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancers.

KanduPay, Inc.

KanduPay, Inc. is a dynamic cryptocurrency exchange, e-Wallet, and remittance solution that facilitates and eases the exchange of fiat & digital currencies, financial transactions, and wallet services across market channels for its platform users supporting major currencies across the globe (KanduPay.com).

XenImmune Therapeutics

XenImmune Therapeutics is developing a novel antibody-enzyme fusion to target tumors and trigger the robust immune response known as hyper-acute rejection.

Pelex, Inc.

Pelex is a digital health platform for pelvic floor disorders built on a proprietary connected medical device. The goal of the company is to revolutionize the patient experience by bringing diagnosis AND treatment of pelvic floor disorders out of the clinic and into the home.

Onasys Controls

Export control for shipping research and clinical materials is complex and fraught with human error. Onasys leverages industry best practice and regulations to ensure your organization is productive, compliant, and safe. Onasys was founded by industry experts at Weill Cornell Medicine and Fitzroy Health.

Soctera, Inc.

Soctera is developing the world’s first aluminum nitride-based power amplifier. These amplifiers will allow higher power operation than other material platforms, such as gallium nitride or silicon. Higher power translates to an increase in the distance a wireless signal can travel. This is of value in markets such as base stations and military radar systems. Soctera plans to expand from this initial product and develop the aluminum nitride platform as the future of high-frequency, high-power electronics.

Soctera spun out of an engineering lab at Cornell University in Ithaca, NY.

IpiNovyx Bio Inc.

IpiNovyx is a biopharmaceutical company that aims to transform the ways autoimmune and inflammatory are treated through a reversable, ultra-potent and non-toxic approach.

Convergent Therapeutics, Inc.

Convergent Therapeutics, Inc. is a clinical stage pharmaceutical company focused on developing next generation radiopharmaceutical therapies for prostate and other cancers. The company’s proprietary technology involves dual-targeted radionuclide therapy (RNT) developed by Dr. Neil Bander, Professor of Urologic Oncology at Weill Cornell Medicine and licensed to Convergent by Cornell University.